AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02452216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Analysis
Description: Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
Study NCT02452216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.
Study NCT02467192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low dose CT
Description: Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist
Study NCT03144336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information provision
Description: All study participants will receive weekly messages with HIV prevention information.
Study NCT03144336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information provision
Description: All study participants will receive weekly messages with HIV prevention information.
Study NCT03144336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly quizzes
Description: Those in the intervention group receive a weekly quiz by text message that gains them points increasing their chances of winning a prize if answered correctly
Study NCT00977379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
Study NCT03144336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rewards for testing HIV-negative
Description: Those in the intervention group are entered into a prize drawing if they test HIV-negative at least once in a three-month period.
Study NCT04181229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Patients will receive surgical implantation of the Medtronic DBS device (Device # 37601). Two (2) electrodes will be implanted bilaterally in the centromedian nucleus.
Study NCT02883660 — intervention group
Intervention type: GENETIC
Intervention: Genocept Assay
Description: battery of pharmacogenetic tests relevant to psychiatry
Study NCT04018924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Illumination with blue light (400-430nm) for 60 seconds with a power density of 120mW/sqcm (EmoLED device)
Description: Debridement and Dressing or compressive dressing if needed
Study NCT00960024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support-vocational rehabilitation
Description: Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
Study NCT00389376 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study NCT00389376 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 140 mg every 8 hours
Study NCT00389376 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 280 mg single dose
Study NCT00389376 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 280 mg single dose + every 8 hours
Study NCT00389376 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 560 mg single dose + every 8 hours
Study NCT00389376 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 280 mg every 8 hours
Study NCT00389376 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Silymarin
Description: 700 mg single dose + every 8 hours
Study NCT02000024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Watchers
Description: The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk.
Study NCT02000024 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers
Description: The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk.
Study NCT02000024 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National Diabetes Education Program
Study NCT02046837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised 1:1 exercise
Description: The exercise program will be delivered in a personal training (1:1) format by a certified exercise specialist.
Study NCT02046837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised group exercise
Description: The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
Study NCT02046837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
Study NCT04575545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serology test for COVID-19
Description: ELISA test
Study NCT01557101 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: COLON CAPSULE ENDOSCOPY ADHERENCE
Description: An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.
Study NCT01557101 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: OPTICAL COLONOSCOPY ADHERENCE
Description: An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
Study NCT05329753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile health application
Description: Health intervention through a smartphone application that favors the process of learning
Study NCT02151786 — intervention group
Intervention type: DRUG
Intervention: Lansoprazole
Description: Lansoprazole intravenous 30 mg
Study NCT02178319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgical procedure
Description: open esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
Study NCT02178319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgical procedure
Description: laparoscopic esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
Study NCT01758562 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Caphosol
Study NCT04115839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets will be administered orally once daily with or without food.
Study NCT04115839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food.
Study NCT04115839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food.
Study NCT00187577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost (Xalatan)
Study NCT00187577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost (Lumigan)
Description: Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.
Study NCT00187577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical application of latanoprost solution to eyelid
Description: Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
Study NCT03744091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P1
Description: 10 mg or 20 mg of THC:THCa
Study NCT00602797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00602797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00602797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00602797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Given IV
Study NCT04736407 — intervention group
Intervention type: OTHER
Intervention: Observational sampling of CSF timed around routine clinical repositioning, or not
Description: no true intervention
Study NCT03588039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets
Study NCT03588039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously administered
Study NCT04194398 — intervention group
Intervention type: DEVICE
Intervention: OCS Lung System
Description: Patients previously transplanted with lungs preserved on the OCS Lung System in the Expand Lung study.
Study NCT03523897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot Assisted Total Knee Replacement
Description: A robotic-assisted surgical procedure to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
Study NCT03523897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Total Knee Replacement
Description: A surgical procedure using mechanical guides to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
Study NCT01277913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 1000 IU once daily for 12 months
Study NCT01277913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 500 IU once daily for 12 months
Study NCT03180242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EG12014
Description: EG12014, single-dose IV infusion over 90 min at 6 mg/kg
Study NCT03180242 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced Herceptin
Description: EU-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
Study NCT03180242 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-sourced Herceptin
Description: US-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
Study NCT02988219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl
Description: Local anesthetic
Study NCT02988219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter ECG monitor
Description: 3-chanel, CM5 leads
Study NCT02988219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holter ECG monitor
Description: 3-chanel, CM5 leads
Study NCT02988219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open kidney cancer surgery
Description: Lateral position
Study NCT02988219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open kidney cancer surgery
Description: Lateral position
Study NCT02988219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Study NCT02988219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Study NCT02988219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Anaesthesia
Study NCT03636113 — intervention group
Intervention type: DEVICE
Intervention: Clarity RMS Electronic Sensor
Description: The urinary foley catheter with electronic sensor will be placed within the Operating Room prior to surgery. Upon arrival to the ICU, the device will be connected to an electronic console by study coordinator. The study coordinator will weigh the urine drainage bag and record the weight every hour for 4-6 hours. The device will record urine flow on a 15 minute interval up to 6 hours
Study NCT01521572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulphate
Description: bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
Study NCT01115088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aspartame
Description: The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
Study NCT01115088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
Study NCT01115088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stevia
Description: The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
Study NCT02137707 — intervention group
Intervention type: DRUG
Intervention: Gilenya
Description: All patients will receive Gilenya
Study NCT06081699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: Oral
Study NCT00803595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-8958
Description: CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
Study NCT00803595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-8958
Description: CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
Study NCT00960024 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocational rehabilitation available
Description: The participants are offered vocational rehabilitation available at site
Study NCT05537194 — intervention group
Intervention type: DRUG
Intervention: dihydropyridine calcium channel inhibitors use
Description: administration of dihydropyridine calcium channel inhibitors
Study NCT06081699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNP-2198 Placebo
Description: The placebo for TNP-2198 active drug
Study NCT03200808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mixed methylene blue compound injection
Description: Every patient received intradermal mixed methylene blue compound injection twice.
Study NCT00078624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional exercise therapy for knee osteoarthritis
Description: Exercises include stretching, strengthening, and aerobic exercise
Study NCT00078624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee stability training
Description: The addition of agility and perturbation training techniques to the traditional exercise program
Study NCT03292913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Health Check
Description: Positive Health Check (PHC) is an online intervention that delivers tailored evidence-based prevention messages to human immunodeficiency virus (HIV) positive patients through a series of brief interactive videos designed to simulate a conversation with an human immunodeficiency virus (HIV) primary care provider.
Study NCT02773368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
Study NCT02773368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: IGlar will be given subcutaneously ( s.c., under the skin) once daily.
Study NCT04342260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Monitoring
Description: The participants randomized to active symptom monitoring will have alerts sent to their clinicians when their PRO symptom scores exceed baseline postoperative scores (when discharge day scores are available) by 2 points or more, or when 'severe' or 'very severe' symptoms are reported.
Study NCT04342260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Monitoring
Description: Participants randomized to the passive PRO monitoring arm will complete the same PROs as participants in the active monitoring arm, but will not have alerts sent to their clinician.
Study NCT02743910 — intervention group
Intervention type: OTHER
Intervention: ptDNA
Description: Pre-operative blood samples for ptDNA will be collected at the time of diagnosis/prior to NAT, post-cycle 1/pre-cycle 2 of NAT, after all NAT/immediately before surgery, and post-operatively at 6, 12, 24, and 36 months, and annually thereafter if funding allows.
Study NCT02743910 — intervention group
Intervention type: OTHER
Intervention: Tissue sample
Description: Representative tissue sample will be collected from the diagnostic biopsy (in all participants) and definitive surgery (if available)
Study NCT02752763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: %40 diluted Autologous serum
Description: Serum that obtained after centrifugation of blood sample
Study NCT02752763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
Description: Preservative free artificial tears is a group naming for drops commonly used for drye disease
Study NCT01646138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ca/04/2009/H1N1 Vero Grown Challenge Virus
Description: The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
Study NCT00979914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education programme
Description: The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
Study NCT03292913 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care for patients with human immunodeficiency virus (HIV) (this includes standard of care practices around antiretroviral therapy (ART) initiation, adherence and retention)
Study NCT00803595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir phosphate
Description: CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.
Study NCT04118075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT-CY-FK +/-ATG
Description: GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
Study NCT04083703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interbody cage insertion in lumbar disc prolapse
Description: Discectomy alone versus interbody cage insertion in treatment of lumbar disc proapse
Study NCT03009162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: 200 mg, single oral tablet
Study NCT03038594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Study NCT03038594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.09% Saline Solution
Study NCT02589314 — intervention group
Intervention type: DEVICE
Intervention: Mechanical periodontal therapy
Study NCT02589314 — intervention group
Intervention type: PROCEDURE
Intervention: nonsurgical periodontal therapy